ACS Medicinal Chemistry Letters
Page 6 of 8
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
refractivity; DCM, dichloromethane; dba,
Dibenzylideneacetone; PK, pharmacokinetics.
Espeseth, A. S.; Jin, L.; Ellis, J.; Holloway, M. K.; Munshi, S.;
Allison, T.; Hazuda, D.; Simon, A. J.; Graham, S. L.; Vacca, J.
P., Macrocyclic Inhibitors of -Secretase: Functional
Activity in an Animal Model. J. Med. Chem 2006, 49 (21),
6147-6150.
REFERENCES
1
.
Foster, J. G.; Blunt, M. D.; Carter, E.; Ward, S. G.,
Inhibition of PI3K Signaling Spurs New Therapeutic
12.
Johnson, T. W.; Richardson, P. F.; Bailey, S.;
Opportunities in Inflammatory/Autoimmune Diseases and
Hematological Malignancies. Pharmacol. Rev. 2012, 64 (4),
Brooun, A.; Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.;
Deng, Y. L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.;
Hoffman, R. L.; Huang, Q.; Kania, R. S.; Kath, J. C.; Lam, H.;
Lam, J. L.; Le, P. T.; Lingardo, L.; Liu, W.; Mctigue, M.;
Palmer, C. L.; Sach, N. W.; Smeal, T.; Smith, G. L.; Stewart,
A. E.; Timofeevski, S.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards,
M. P., Discovery of (10R)-7-amino-12-fluoro-2,10,16-
trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-
(metheno)pyrazolo[4,3-H][2,5,11]-
benzoxadiazacyclotetradecine-3-carbonitrile (PF-
06463922), A Macrocyclic Inhibitor of Anaplastic
Lymphoma Kinase (ALK) and C-Ros Oncogene 1 (ROS1)
with Preclinical Brain Exposure and Broad-Spectrum
Potency Against ALK-Resistant Mutations. J. Med. Chem
2014, 57 (11), 4720-4744.
1
2
027-1054.
Engelman, J. A.; Luo, J.; Cantley, L. C., The
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
.
Evolution of Phosphatidylinositol 3-Kinases as Regulators
of Growth and Metabolism. Nat. Rev. Genet. 2006, 7, 606.
3
.
Mcnamara, C. R.; Degterev, A., Small-Molecule
Inhibitors of the PI3K Signaling Network. Future Med.
Chem. 2011, 3 (5), 549-565.
4
.
Down, K.; Amour, A.; Baldwin, I. R.; Cooper, A. W.
J.; Deakin, A. M.; Felton, L. M.; Guntrip, S. B.; Hardy, C.;
Harrison, Z. A.; Jones, K. L.; Jones, P.; Keeling, S. E.; Le, J.;
Livia, S.; Lucas, F.; Lunniss, C. J.; Parr, N. J.; Robinson, E.;
Rowland, P.; Smith, S.; Thomas, D. A.; Vitulli, G.; Washio,
Y.; Hamblin, J. N., Optimization of Novel Indazoles as
Highly Potent and Selective Inhibitors of Phosphoinositide
13.
Mccoull, W.; Abrams, R. D.; Anderson, E.; Blades,
3
-Kinase δ for the Treatment of Respiratory Disease. J.
Med. Chem. 2015, 58 (18), 7381-7399.
Finan, P. M.; Thomas, M. J., PI 3-Kinase Inhibition:
K.; Barton, P.; Box, M.; Burgess, J.; Byth, K.; Cao, Q.;
Chuaqui, C.; Carbajo, R. J.; Cheung, T.; Code, E.; Ferguson,
A. D.; Fillery, S.; Fuller, N. O.; Gangl, E.; Gao, N.; Grist, M.;
Hargreaves, D.; Howard, M. R.; Hu, J.; Kemmitt, P. D.;
Nelson, J. E.; O’Connell, N.; Prince, D. B.; Raubo, P.;
Rawlins, P. B.; Robb, G. R.; Shi, J.; Waring, M. J.; Whittaker,
D.; Wylot, M.; Zhu, X., Discovery of Pyrazolo[1,5-
A]Pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and
Optimization to High Affinity Macrocyclic Inhibitors. J.
Med. Chem. 2017, 60 (10), 4386-4402.
5
.
A Therapeutic Target for Respiratory Disease. Biochem.
Soc. Trans. 2004, 32 (2), 378-382.
6
.
To, Y.; Ito, K.; Kizawa, Y.; Failla, M.; Ito, M.;
Kusama, T.; Elliott, W. M.; Hogg, J. C.; Adcock, I. M.;
Barnes, P. J., Targeting Phosphoinositide-3-Kinase-δ with
Theophylline Reverses Corticosteroid Insensitivity in
Chronic Obstructive Pulmonary Disease. Am. J. Resp. Crit.
Care 2010, 182 (7), 897-904.
14.
Mann, A., Conformational Restriction and/or
7
.
Furman, R. R.; Sharman, J. P.; Coutre, S. E.;
Steric Hindrance in Medicinal Chemistry Wermuth CG
(Ed.). Academic Press, London, UK (2008). In The Practice
of Medicinal Chemistry, Wermuth CG (Ed.). Academic
Press, London, UK: 2008.
Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.;
Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; Eradat, H.;
Ervin, T.; Lamanna, N.; Coiffier, B.; Pettitt, A. R.; Ma, S.;
Stilgenbauer, S.; Cramer, P.; Aiello, M.; Johnson, D. M.;
Miller, L. L.; Li, D.; Jahn, T. M.; Dansey, R. D.; Hallek, M.;
O'Brien, S. M., Idelalisib and Rituximab in Relapsed Chronic
Lymphocytic Leukemia. New Eng. J. Med. 2014, 370 (11),
997-1007.
15.
William, A. D.; Lee, A. C.-H.; Blanchard, S.;
Poulsen, A.; Teo, E. L.; Nagaraj, H.; Tan, E.; Chen, D.;
Williams, M.; Sun, E. T.; Goh, K. C.; Ong, W. C.; Goh, S. K.;
Hart, S.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood,
J. M.; Dymock, B. W., Discovery of the Macrocycle 11-(2-
Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-
tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-
1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), A
Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3
(JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis
and Lymphoma. J. Med. Chem 2011, 54 (13), 4638-4658.
8.
Bieth, B.; Burkhart, C.; Christ, A.; De Buck, S.;
Kalis, C.; Lindgren, S. Use of Inhibitors of the Activity or
Function of PI3K for the Treatment of Primary Sjoegren's
Syndrome. WO2017118965A1, 2017.
9.
Driggers, E.; Hale, S.; Lee, J.; Terrett, N. K., The
Exploration of Macrocycles for Drug Discovery — An
Underexploited Structural Class., Nat. Rev. Drug Discov.,
2008, 7, 608–624.
16.
Moree, W. J.; Van Gent, L. C.; Van Der Marel, G.
A.; Liskamp, R. M. J., Synthesis of Peptides Containing a
Sulfinamide or a Sulfonamide Transition-State Isostere.
Tetrahedron 1993, 49 (5), 1133-1150.
10.
Giordanetto, F.; Kihlberg, J. Macrocyclic Drugs
and Clinical Candidates: What Can Medicinal Chemists
Learn From Their Properties? J. Med. Chem. 2014, 57 (2),
17.
Sutherland, H.; Shriner, R. L., Anomalous
2
1
78-295.
1.
Mutarotation of Salts of Reychler's Acid. IV. Comparison of
2-(N-Phenylketimine)-D-Camphane-10-Sulfonic Acid with
Stachel, S. J.; Coburn, C. A.; Sankaranarayanan, S.;
Price, E. A.; Pietrak, B. L.; Huang, Q.; Lineberger, J.;
ACS Paragon Plus Environment